Unlocking Clinical Support for Cell and Gene Therapies
Monitor cell and gene therapy patients through PET imaging
Revolutionizing Cell Therapy Monitoring & Analysis
Through precise monitoring and analysis, we empower healthcare professionals and researchers with the knowledge needed to make informed clinical decisions, ultimately advancing the field of medical research and enhancing patient outcomes.
Our innovative approach enables early identification of cell therapy patients that will fail to achieve complete remissions or experience treatment-induced toxicity using PET-CT scans. These timely insights would help physicians choose when to rescue ineffective therapies or administer preventative toxicity-mitigating treatments.
Technology
Accurate prognosis of cancer patients receiving cell therapy treatments is critical to managing therapy-induced adverse effects, which can result in ICU admission or even death. Positron emission tomography (PET) scans can be used to anticipate oncoming toxicities and enable physicians to administer preventative treatments, but creating PET-detectable cell therapies has proven challenging because the immune system recognizes them as a foreign pathogen. Our unique PET reporter technology is designed to be invisible to the human immune system, facilitating clinical progression.
Benefits
Intelligence & Data
Researchers will gain access to a new data source that will help inform the next generation of therapies by providing quantitative metrics with high level of accuracy. And because PET scans are non-invasive, physicians will be able to monitor patient populations where other methods (e.g., serial biopsies) are not ethical (e.g., children) or possible (e.g., multiple tumor sites).
Finance & Operations
Researchers and pharmaceutical companies will be able to reduce the cost and time allocated to unsuccessful trials, freeing resources for clinical development of successful therapies and accelerating their time-to-market.
Clinical Efficacy & Patient Safety
Our PET reporter technology will enable physicians monitor patients, and employ treatment rescuing or toxicity mitigation strategies in a timely manner.
Meet The Team
Dr. Yaniv Tivon has over 7 years of experience in cell therapy development in both academic and industry settings. His graduate research at the University of Pittsburgh was focused on engineering a CAR T cell therapy that can be turned in case severe toxicities emerge.
He later joined Legend Biotech, where he advanced cell therapies that target difficult-to-treat tumors. At another company, BlueRock Therapeutics, he designed and executed projects aimed to develop stem cell therapies to treat Parkinson’s Disease. His experience in early-stage research and project management are integral to developing the company’s platform technology.
Gilbert Brook is NeoCell Technologies’ business lead and has 8 years of experience in the healthcare sector. He began his career in immuno-oncology research at the Children’s Hospital of Philadelphia, working on research for Stand Up to Cancer. Then, he worked in investment banking at Locust Walk, advising biotechnology and biopharmaceutical companies through strategic and financial decisions.
He later joined Sandbox Advisers, a management consulting firm that advises large U.S. healthcare payers, primarily focused on creating new lines of business and evaluating growth opportunities. His healthcare and business experience will be integral to the development of the company and the commercialization strategy of its products.
Dr. Jason Lohmueller serves as NeoCell Technologies’ Scientific Advisor. As an assistant professor in the department of surgery in the University of Pittsburgh Medical Center, he has over a decade of experience in engineering cell therapies.
His lab is focused on the development and preclinical assessment of promising CAR T cell technologies, and he previously collaborated with Dr. Yaniv Tivon on the development of a multi-antigen targeting CAR T cell platform (now licensed to Coeptis Therapeutics for clinical development). His expertise in CAR T cell design and evaluation are essential to NeoCell Technologies’ success.
